Literature DB >> 27160405

The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis.

Meghan E Free1, Ronald J Falk2.   

Abstract

Entities:  

Keywords:  ANCA vasculitis; biomarker; relapse; remission

Mesh：

Substances：

Year:  2016        PMID： 27160405      PMCID： PMC5004669          DOI： 10.1681/ASN.2016030347

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  13 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding.

Authors:  Holger Jon Møller; Marianne Jensby Nielsen; Maciej Bogdan Maniecki; Mette Madsen; Søren Kragh Moestrup
Journal:  Immunobiology       Date:  2009-07-05       Impact factor: 3.144

Review 4.  Treatment of ANCA-associated systemic small-vessel vasculitis.

Authors:  David Jayne
Journal:  APMIS Suppl       Date:  2009-06

5.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rachel B Jones; Alastair J Ferraro; Afzal N Chaudhry; Paul Brogan; Alan D Salama; Kenneth G C Smith; Caroline O S Savage; David R W Jayne
Journal:  Arthritis Rheum       Date:  2009-07

6.  Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; John C Davis; Gary S Hoffman; W Joseph McCune; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

7.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.

Authors:  Hong Xiao; Peter Heeringa; Peiqi Hu; Zhi Liu; Minglang Zhao; Yasuaki Aratani; Nobuyo Maeda; Ronald J Falk; J Charles Jennette
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

8.  Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Eugene P Rhee; Karen A Laliberte; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

9.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

10.  Persistent hematuria after induction of remission in Wegener granulomatosis: a therapeutic dilemma.

Authors:  Marina N Magrey; Alexandra Villa-Forte; Curry L Koening; Jonathan L Myles; Gary S Hoffman
Journal:  Medicine (Baltimore)       Date:  2009-11       Impact factor: 1.889
View more
  1 in total

Review 1.  Vasculitis update: pathogenesis and biomarkers.

Authors:  Paul Brogan; Despina Eleftheriou
Journal:  Pediatr Nephrol       Date:  2017-08-07       Impact factor: 3.714
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.